Twenty U.S. states including California, Connecticut and Michigan have pushed back against a $10 million settlement that Florida reached with Swiss generic drugmaker Sandoz, saying a key provision ...
Osteoporosis drug Prolia faces intense competition as patents expire and generics launch Intense rivalry emerges in the ...
Your doctor may have prescribed it for another reason. Cyclosporin Sandoz is only available with a doctor's prescription. It is not addictive. Do not take Cyclosporin Sandoz if you have ever had ...
Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first financial year as an independent company. After completing its spin-off from ...
A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side ...
Like rivals Teva Pharmaceutical Industries Ltd. and Viatris Inc., Sandoz copies branded drugs once they lose patent protection, which leads to reduced costs. It manufactures those products largely ...
Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...
Four companies have applied to Health Canada to sell copies of Ozempic after its market exclusivity expires on Jan. 4, 2026 ...
Like rivals Teva Pharmaceutical Industries Ltd. and Viatris Inc., Sandoz copies branded drugs once they lose patent protection, which leads to reduced costs. It manufactures those products largely ...
With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...
A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback